The Role of Prokineticin 2 in Oxidative Stress and in Neuropathological Processes.

Prokineticin receptor antagonists neurodegenerative diseases neurotoxicity prokineticin 2 prokineticin receptors

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2021
Historique:
received: 11 12 2020
accepted: 28 01 2021
entrez: 18 3 2021
pubmed: 19 3 2021
medline: 19 3 2021
Statut: epublish

Résumé

The prokineticin (PK) family, prokineticin 1 and Bv8/prokineticin 2 (PROK2), initially discovered as regulators of gastrointestinal motility, interacts with two G protein-coupled receptors, PKR1 and PKR2, regulating important biological functions such as circadian rhythms, metabolism, angiogenesis, neurogenesis, muscle contractility, hematopoiesis, immune response, reproduction and pain perception. PROK2 and PK receptors, in particular PKR2, are widespread distributed in the central nervous system, in both neurons and glial cells. The PROK2 expression levels can be increased by a series of pathological insults, such as hypoxia, reactive oxygen species, beta amyloid and excitotoxic glutamate. This suggests that the PK system, participating in different cellular processes that cause neuronal death, can be a key mediator in neurological/neurodegenerative diseases. While many PROK2/PKRs effects in physiological processes have been documented, their role in neuropathological conditions is not fully clarified, since PROK2 can have a double function in the mechanisms underlying to neurodegeneration or neuroprotection. Here, we briefly outline the latest findings on the modulation of PROK2 and its cognate receptors following different pathological insults, providing information about their opposite neurotoxic and neuroprotective role in different pathological conditions.

Identifiants

pubmed: 33732160
doi: 10.3389/fphar.2021.640441
pii: 640441
pmc: PMC7956973
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

640441

Informations de copyright

Copyright © 2021 Lattanzi, Severini, Maftei, Saso and Badiani.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Arterioscler Thromb Vasc Biol. 2008 May;28(5):841-9
pubmed: 18421008
J Neuroimmunol. 1999 Jan 1;93(1-2):182-93
pubmed: 10378882
J Cereb Blood Flow Metab. 2003 Nov;23(11):1324-39
pubmed: 14600440
Neuropharmacology. 2019 Nov 1;158:107739
pubmed: 31408628
Physiol Rev. 2018 Apr 1;98(2):1055-1082
pubmed: 29537336
Life Sci. 2007 Sep 15;81(14):1103-16
pubmed: 17881008
Mov Disord. 2021 Jan 6;:
pubmed: 33404134
Aging Dis. 2019 Jun 01;10(3):664-675
pubmed: 31165009
Mol Pharmacol. 2001 Apr;59(4):692-8
pubmed: 11259612
J Comp Neurol. 2006 Oct 20;498(6):796-809
pubmed: 16927269
Mol Neurobiol. 1996 Feb;12(1):73-94
pubmed: 8732541
Curr Med Chem. 2018;25(32):3883-3894
pubmed: 28707588
J Neuropathol Exp Neurol. 2008 Jan;67(1):78-84
pubmed: 18091557
J Neurosci Res. 2008 Jun;86(8):1659-69
pubmed: 18189318
Neurobiol Aging. 2000 May-Jun;21(3):383-421
pubmed: 10858586
Nat Protoc. 2007;2(1):141-51
pubmed: 17401348
N Engl J Med. 1994 Mar 3;330(9):613-22
pubmed: 7905600
J Alzheimers Dis. 2014;38(2):281-93
pubmed: 23948942
Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5475-80
pubmed: 22431614
Eur J Neurosci. 2012 Jul;36(1):1993-2005
pubmed: 22639866
FEBS Lett. 1999 Nov 19;461(3):183-8
pubmed: 10567694
FASEB J. 2000 May;14(7):955-67
pubmed: 10783150
Hum Mol Genet. 2010 Apr 15;19(R1):R12-20
pubmed: 20413653
Front Pharmacol. 2019 Sep 12;10:1008
pubmed: 31572186
Int Rev Neurobiol. 2009;85:145-57
pubmed: 19607967
J Neurochem. 2005 Feb;92(4):948-61
pubmed: 15686497
Front Pharmacol. 2019 May 29;10:622
pubmed: 31231219
PLoS One. 2015 Apr 01;10(4):e0121027
pubmed: 25831128
Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):345-352
pubmed: 31899964
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S185-8
pubmed: 20082987
Neuropharmacology. 2016 Sep;108:39-48
pubmed: 27140692
Glia. 2018 Oct;66(10):2137-2157
pubmed: 30277602
Eur J Neurosci. 2001 May;13(9):1694-702
pubmed: 11359521
Biomed Res Int. 2015;2015:301292
pubmed: 25685780
Science. 2005 Jun 24;308(5730):1923-7
pubmed: 15976302
Neuropharmacology. 2017 Apr;116:82-97
pubmed: 27989680
Sci Rep. 2015 Oct 19;5:15301
pubmed: 26477583
J Med Chem. 2008 Dec 11;51(23):7635-9
pubmed: 19006379
ScientificWorldJournal. 2012;2012:756357
pubmed: 22566778
Br J Pharmacol. 2005 Nov;146(5):625-32
pubmed: 16113687
J Biol Chem. 2002 May 31;277(22):19276-80
pubmed: 11886876
Oxid Med Cell Longev. 2020 May 18;2020:3163629
pubmed: 32509142
Brain Res. 2006 Sep 27;1112(1):65-9
pubmed: 16901473
Eur J Pharmacol. 1999 Jun 18;374(2):189-96
pubmed: 10422759
J Neurosci. 2012 Dec 5;32(49):17775-87
pubmed: 23223297
FASEB J. 2007 Sep;21(11):2980-93
pubmed: 17442730
Eur J Med Chem. 2014 Jun 23;81:334-40
pubmed: 24852280
PLoS One. 2009 Sep 28;4(9):e7151
pubmed: 19784373
Nature. 2002 May 23;417(6887):405-10
pubmed: 12024206
Br J Pharmacol. 2014 Nov;171(21):4850-65
pubmed: 24902717
Cells. 2019 Nov 13;8(11):
pubmed: 31766244
Mol Neurobiol. 2006 Dec;34(3):249-70
pubmed: 17308356
Biochim Biophys Acta. 2002 Dec 12;1579(2-3):173-9
pubmed: 12427552
J Neurosci. 2005 Oct 19;25(42):9794-806
pubmed: 16237183
Nat Commun. 2016 Oct 05;7:12932
pubmed: 27703142

Auteurs

Roberta Lattanzi (R)

Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Rome, Italy.

Cinzia Severini (C)

Institute of Biochemistry and Cell Biology, IBBC, CNR, Rome, Italy.

Daniela Maftei (D)

Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Rome, Italy.

Luciano Saso (L)

Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Rome, Italy.

Aldo Badiani (A)

Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Rome, Italy.

Classifications MeSH